Shire LLC v. Anchen Pharmaceuticals Inc.,et al
1:10-cv-00484
Overview
Parties
Defendant
Supernus Pharmaceuticals Inc. Operating Company
Represented By
4 Attorneys ListedFaegre Drinker Biddle & Reath LLP
222 Delaware Avenue, Suite 1410
Anchen Pharmaceuticals Inc. Operating Company
Represented By
1 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Anchen Inc. Operating Company
Represented By
1 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Shire LLC Operating Company
Represented By
4 Attorneys ListedFaegre Drinker Biddle & Reath LLP
222 Delaware Avenue, Suite 1410
Plaintiff
Robert D. Hunt MD Operating Company
Represented By
4 Attorneys ListedFaegre Drinker Biddle & Reath LLP
222 Delaware Avenue, Suite 1410
Pasko Rakic MD NPE (Individual / Inventor)
Represented By
4 Attorneys ListedFaegre Drinker Biddle & Reath LLP
222 Delaware Avenue, Suite 1410
Amy F.T. Arnsten PHD Operating Company
Represented By
4 Attorneys ListedFaegre Drinker Biddle & Reath LLP
222 Delaware Avenue, Suite 1410
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Shire LLC, Supernus Pharmaceuticals, Incl v. IMPAX Laboratories, Inc.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5854290
Use of guanfacine in the treatment of behavioral disorders
|
Filed: 1995-09-21
Issued: 1998-12-29
|
Expired (Term Ended)
Expires: 2015-09-21
|
|
|
US6287599
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
Filed: 2000-12-20
Issued: 2001-09-11
|
Expired (Term Ended)
Expires: 2020-12-20
|
|
|
US6811794
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
Filed: 2001-12-20
Issued: 2004-11-02
|
Expired (Term Ended)
+196d PTA
Expires: 2022-07-04
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).